Long-term changes in glucose metabolism after gestational diabetes: a double cohort study by unknown
Huopio et al. BMC Pregnancy and Childbirth 2014, 14:296
http://www.biomedcentral.com/1471-2393/14/296RESEARCH ARTICLE Open AccessLong-term changes in glucose metabolism after
gestational diabetes: a double cohort study
Hanna Huopio1*, Heidi Hakkarainen2, Mirja Pääkkönen3, Teemu Kuulasmaa4, Raimo Voutilainen1,
Seppo Heinonen2 and Henna Cederberg5Abstract
Background: Gestational diabetes (GDM) has been associated with an elevated risk of type 2 diabetes in women
after the pregnancy. Recognition of the factors differentiating the women at highest risk of progression to overt
disease from those who remain normoglycemic after gestational diabetes is of key importance for targeted
prevention programmes. To this aim, we investigated the incidence and risk factors of prediabetes and type 2
diabetes with a view to the underlying pathophysiological mechanisms in a long-term follow-up of women with a
history of gestational diabetes.
Methods: 489 women with GDM and 385 normoglycemic controls attended a follow-up study after pregnancy
(mean follow-up time 7.3, SD 5.1 years) in Kuopio, Finland. Glucose tolerance was evaluated with an oral glucose
tolerance test, insulin sensitivity by Matsuda insulin sensitivity index (ISI), and insulin secretion by Disposition Index
30 (DI30).
Results: GDM increased risk of pre-diabetes and diabetes (HR 3.7, 95% C.I. 2.8-4.7 and HR 40.7, 95% C.I. 5.3-310.1,
respectively, after adjustment for confounding factors) and was associated with both increased fasting (P < 0.001)
and 2-hour plasma glucose (P < 0.001) during OGTT at the follow-up study. This effect was attenuated when adjusted for
Matsuda ISI but abolished after adjustments with DI30 suggesting insulin secretion is the key defect leading to type 2
diabetes after GDM pregnancy. Increase in waist circumference and weight after pregnancy predicted the development
of hyperglycemic conditions in women with a history of GDM (P < 0.001, and P = 0.002, respectively).
Conclusions: Pre-diabetic stages after GDM pregnancy are frequent and reflect the progressive risk of type 2 diabetes in
long-term follow-up. Hyperglycemia after GDM pregnancy results from beta cell failure and inability to compensate the
increased insulin resistance by insulin secretion. Importantly, increase in waist circumference and as well as weight gain
during the follow-up is associated with progression to prediabetes and type 2 diabetes in women with a history GDM.
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Gestational diabetes (GDM) is defined as glucose intoler-
ance detected for the first time during pregnancy. The
prevalence of GDM is on the increase and currently affects
2–14% of all pregnancies [1,2], and is associated with mark-
edly elevated risk of both maternal and fetal complications
[3]. During pregnancy, insulin resistance increases and
when accompanied by impaired beta cell function, the risk
of GDM increases. After the pregnancy glucose tolerance* Correspondence: hanna.huopio@kuh.fi
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unless otherwise stated.normalizes, but previous studies have demonstrated that
affected women have at least a seven-fold risk of develop-
ing type 2 diabetes later in life [4-7].
Impaired insulin secretion and insulin resistance are the
two main metabolic disturbances in the pathogenesis of
type 2 diabetes and often coexist [6]. Previous studies have
shown that type 2 diabetes usually develops due to insuffi-
cient pancreatic insulin secretion to compensate for the
existing insulin resistance. Insulin resistance is present
early in the natural history of type 2 diabetes and marked
beta-cell dysfunction is a rather late event [8]. Both insulin
resistance and beta-cell dysfunction are also features of
GDM. Both of these disturbances in glucose metabolismLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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but behavioural and environmental factors like obesity
and physical inactivity are emphasized in the development
of insulin resistance while genetic factors have a stronger
influence on the insulin secretion [10].
Type 2 diabetes is preceded by a pre-diabetic stage char-
acterized by mild-to-moderate elevation of fasting and/or
postprandial glucose levels [11]. Impairment in insulin sen-
sitivity is present already at relatively low plasma glucose
levels within the normoglycemic range, years before the
development of overt type 2 diabetes. Pre-diabetic states,
defined by an oral glucose tolerance test (OGTT), include
isolated impaired fasting glucose (IIFG), isolated impaired
glucose tolerance (IIGT), or a combination of these (IFG +
IGT) [6], and represent metabolic states in the continuum
between normal glucose tolerance and diabetic hypergly-
cemia. Both IFG and IGT similarly predict incident dia-
betes, with the highest risk in individuals with combined
IFG and IGT [11]. Previous studies have shown that up to
60% of individuals who have either IGT or IFG will subse-
quently develop overt diabetes. IFG and IGT differ meta-
bolically and therefore identify different risk groups for
impaired glucose regulation. The inability to maintain ad-
equate basal insulin secretion and to control hepatic glu-
cose output is characteristic for IIFG. In contrast, IIGT is
associated with peripheral insulin resistance, especially at
the level of skeletal muscle [11].
Compelling evidence from randomized controlled life-
style intervention trials has shown that up to 58% reduc-
tion in the risk of type 2 diabetes can be achieved by
dietary modifications and increased physical activity in
individuals with IGT [12,13]. Therefore, well-organized
follow-up of women with a history of GDM and timely
diagnosis of pre-diabetic states are crucial for targeted
intervention to prevent development of overt type 2 dia-
betes. In this current study, we evaluated glucose toler-
ance in women after GDM pregnancy (N = 489) and in
healthy controls (N = 385) in a longitudinal long-term
follow-up study, and investigated the pathophysiological
mechanism and risk factors underlying the deterioration
of glucose tolerance and development of prediabetes and
type 2 diabetes following GDM pregnancy.
Methods
The study population was collected from an existing clin-
ical pregnancy registry at the Kuopio University Hospital,
Kuopio, Finland. All patients who had OGTT during preg-
nancy between 1989 and 2009 were contacted by a letter
and invited for the study. A total of 489 previously non-
diabetic women were identified who were diagnosed with
GDM between the years 1989 and 2009; 385 women with
normal glucose tolerance in an oral glucose tolerance test
(OGTT, 75 g glucose dose after overnight fasting) during
pregnancy served as controls. Women with a diagnosis oftype 1 diabetes or late-onset autoimmune diabetes (LADA)
were excluded from the study. For patients with more than
one delivery during the study period, the first pregnancy
with GDM was considered as the index pregnancy.
Women with multiple pregnancy were excluded. Among
participants with GDM, 71.6% had GDM in one preg-
nancy, 21.2% in two pregnancies, 6.3% in three pregnancies
and 0.9% in four pregnancies. The diagnosis of GDM
was based on the contemporary criteria: fasting blood
glucose > 4.8 mmol/l, 1- hour blood glucose >10.0 mmol/l
and 2-hour blood glucose >8.7 mmol/l until September
2001, and since September 2001 fasting plasma glucose
(FPG) > 4.8 mmol/l, 1-hour plasma glucose (PG) >
11.2 mmol/l and 2-hour plasma glucose >9.9 mmol/l.
One or more elevated values during an OGTT resulted
in the diagnosis of GDM.
Follow-up study
All participants attended a 1-day visit at the Kuopio Uni-
versity hospital between years 2006 and 2009. Data on
background characteristics and lifestyle was collected with
questionnaires and interview with a trained study nurse.
Smoking status was defined as current smoking (yes vs.
no). Physical activity (physically active vs. inactive) refers
to leisure time exercise (physically active, regular exercise
at least 30 min 1 or 2 times per week vs. physically in-
active, occasional exercise or no exercise). Data on all
pregnancies was obtained with a questionnaire and parity
was defined as the total number of pregnancies.
Clinical measurements
Height and weight were measured to the nearest 0.5 cm
and 0.1 kg, respectively. BMI was calculated as weight
(kg) divided by height (m) squared.
OGTT
To study the glucose tolerance after the pregnancy, a 2-
hour OGTT (75 g of glucose) was performed in all women
(mean follow-up 7.3, SD 5.1 years), and samples for plasma
glucose and insulin were drawn at 0, 30, and 120 min. Glu-
cose tolerance was evaluated based on OGTT as follows:
NGT (FPG < 5.6 mmol/l and 2-h PG < 7.8 mmol/l), isolated
IFG (IIFG) (FPG 5.6-6.9 mmol/l and 2-h PG < 7.8 mmol/l),
isolated IGT (IIGT)(FPG < 5.6 mmol/l and 2-h PG 7.8-
11.0 mmol/l), IFG and IGT(IFG + IGT) FPG 5.6-6.9 mmol/
l and 2-h PG 7.8-11.0 mmol/l), and newly diagnosed type 2
diabetes (FPG ≥ 7.0 mmol/l and/or 2-h PG ≥ 11.1 mmol/l)
[6]. Prediabetes encompasses both isolated IFG and iso-
lated IGT as well as their combination. Fifteen women had
started an anti-diabetic medication between the index
pregnancy and the follow-up study visit and 14 were diag-
nosed with incident type 2 diabetes at the follow-up study
visit.
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Plasma glucose was measured by enzymatic hexokinase
photometric assay (Konelab Systems reagents; Thermo
Fischer Scientific, Vantaa, Finland). Insulin was deter-
mined by immunoassay (ADVIA Centaur Insulin IRI no.
02230141; Siemens Medical Solutions Diagnostics, Tar-
rytown, NY). HbA1c was measured using the high-
performance liquid chromatography assay (TOSOH G7
glycohemoglobin analyzer, Tosoh Bioscience Inc, San
Francisco, CA), calibrated to DCCT standard. The trap-
ezoidal method was used to calculate glucose area under
the curve (AUC) and insulin AUC during the OGTT.
Calculation of insulin sensitivity (Matsuda ISI), insulin
secretion (InsAUC0-30/GluAUC0-30) and disposition
indices (DI30) have been previously described [14].Statistical analysis
All statistical analyses were performed using SPSS 19
statistical software (SPSS, Chicago, IL). Anthropometric
and biochemical variables were log-transformed to cor-
rect for their skewed distribution as appropriate. Com-
parisons between women with GDM and corresponding
controls, as well as comparisons between the GDM sub-
jects with abnormal glucose tolerance and NGT (mean,
standard deviation, SD) were done using t-test for con-
tinuous and Chi2 test for categorical variables. The risk
of prediabetic stages (including IIFG/IIGT/IFG + IGT) in
GDM patients and controls was evaluated by Cox pro-
portional hazards regression models, and adjusted for
age, BMI, parity, the traditional risk factors for type 2
diabetes including current smoking and physical activity
(physically active, regular exercise at least 30 min a week
vs. physically less active, occasional exercise or no exer-
cise). The risk of incident type 2 diabetes in patients
with GDM and controls was compared with Cox pro-
portional hazards regression model. Linear regression
analysis was used to evaluate the association of GDM
status in index pregnancy with hyperglycemia at follow-
up, and adjusted for age and BMI at follow-up study,
follow-up time, parity, current smoking, and physical ac-
tivity. The participants with type 2 diabetes diagnosed
during the follow-up time and started on anti-diabetic
medication (N = 15) were not included in the linear re-
gression analysis. P < 0.05 was considered statistically
significant.Ethical considerations
The study was approved by the local ethics committee
of the Kuopio University Hospital, and it was conducted
in accordance with the Helsinki Declaration. All study
participants gave written informed consent.
The study has adhered to the STROBE guidelines for
observational studies.Results
The clinical and laboratory characteristics of the study
groups are presented in Table 1. Participants with GDM
were older (P < 0.001) and had higher BMI than the con-
trols in the first trimester of the index pregnancy (P <
0.001). 36.6% of the GDM group had their first preg-
nancy as an index pregnancy whereas the corresponding
rate was 54.5% in the control group (P < 0.001). The
mean total number of pregnancies were 1.1 (SD = 1.3)
and 0.7 (SD = 0.9) in women with a history of GDM and
control women, respectively. No differences were ob-
served in the duration of the pregnancy or in the birth
weight of the child between the study groups. The
follow-up time was shorter in the GDM patients as com-
pared to controls (P < 0.001). At the follow-up study
visit, GDM patients had higher BMI (P < 0.001), HbA1c
(P < 0.001), glucose and insulin levels during an OGTT,
and they were more insulin resistant than the control
subjects (Matsuda ISI, P < 0.001). Insulin sensitivity-
corrected insulin secretion (DI30) was significantly de-
creased in the GDM subjects (P < 0.001) as compared to
the controls.
The distribution of the GDM and control subjects ac-
cording to the state of glucose tolerance in the OGTT at
the follow-up study visit is shown in Figure 1. 47% of
the GDM subjects and 74% of the controls had normal
glucose tolerance at the follow-up study visit (P < 0.001).
Prediabetes (isolated IFG, isolated IGT, or IFG& IGT)
was detected in 48% of the GDM subjects and 26% of
the controls (P 0.001). Isolated impaired fasting glucose
(IIFG) was found in 37 vs. 22% (P < 0.001), isolated im-
paired glucose tolerance (IIGT) in 4 vs. 2% (P = 0.001),
and IFG + IGT in 6 vs. 3% (P < 0.001) of GDM subjects
and controls, respectively. During the follow-up time
after the index pregnancy, none of the normoglycemic
controls had proceeded to diabetes, whereas 15 (3.1%)
subjects in the GDM group had been diagnosed with
type 2 diabetes and started on anti-diabetic medication.
At the follow-up visit, diabetes was diagnosed by OGTT
in one (0.3%) control and further 13 (2.7%) GDM sub-
jects. Figure 2 illustrates the risk of developing diabetes
(the time point of diagnosis) during the course of the
follow-up time (HR 40.7, 95% CI 5.3-310.1). The risk
was minimal and linear in the control population but in-
creased markedly in the GDM group especially after
10 years of follow-up.
The association between GDM and glucose toler-
ance at the follow-up study was evaluated by Cox
proportional hazard model (Table 2). GDM increased
the risk of pre-diabetes [(HR 4.0 (95% C.I. 3.1–5.1)]
in all categories of glucose tolerance status [(IIFG:
HR 3.1 (95% C.I. 2.4-4.0), IIGT: HR 7.8 (95% C.I.
2.9-21.6), IFG + IGT: HR 4.7 (95% C.I. 2.2-10.0)].
The pre-diabetes-increasing risk of GDM remained
Table 1 Clinical characteristics of the women with gestational diabetes and controls at index pregnancy and the
follow-up study
GDM patients (n = 489) Controls (n = 385)
Mean SD Mean SD P
Index pregnancy
Age at delivery (yrs) 32.0 5.9 29.6 5.3 <0.001
Parity 1.1 1.3 0.7 0.9 <0.001
Primipara/multipara (%) 36.6/63.4 54.5/45.6 <0.001
Waist (cm) 91.3 13.4 86.3 11.7 <0.001
BMI in the first trimester (kg/m2) 26.4 4.8 24.1 3.8 <0.001
Duration of the pregnancy (weeks) 39.3 1.5 39.5 1.7 0.095
Birth weight of the child (g) 3648 545 3579 570 0.065
Follow-up study*
Age at follow up (yrs) 37.8 7.2 38.4 6.3 0.200
Follow-up time (yrs) 6.0 4.4 9.0 5.5 <0.001
Family history of diabetes (%) 81.0 71.5 0.001
Current smoker (%) 18.8 13.6 0.040
BMI (kg/m2) 28.4 5.5 26.9 4.9 <0.001
HbA1c [mmol/mol (%)] 36 (5.5) 5 35 (5.3) 3 <0.001
Fasting plasma glucose (mmol/l) 5.6 0.5 5.3 0.4 <0.001
30-min plasma glucose (mmol/l) 8.0 1.7 7.1 1.5 <0.001
2-h plasma glucose (mmol/l) 6.0 1.7 5.5 1.2 <0.001
Fasting plasma insulin (pmol/l) 79.2 55.6 63.2 43.1 <0.001
30-min plasma insulin (pmol/l) 507.0 355.6 439.0 266 0.013
2-hour plasma insulin (pmol/l) 351.4 327.1 278.5 242.4 <0.001
P-glucose area under the curve (mmol/l*min) 832.6 160.3 749.6 130.6 <0.001
P-insulin area under the curve (pmol/l*min) 40880.3 28499.6 34414 21656 <0.001
HOMA-IR 2.9 2.1 2.2 1.6 <0.001
Matsuda ISI (mg/dl, mU/l) 5.7 3.2 7.1 3.6 <0.001
Disposition Index 167.4 65.1 206.3 77.6 <0.001
*Individuals diagnosed with type 2 diabetes during the follow-up time (n = 15) were not included in HbA1C and oral glucose tolerance tests. HOMA-IR,
homeostatic model assessment of insulin resistance. P-values < 0.05 are indicated in bold font.
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follow-up time, smoking, and physical activity in all
categories of prediabetes.
The association between GDM at index pregnancy and
subsequent hyperglycemia analyzed by linear regression
analysis at the follow-up study is shown in Table 3. A
strong association between GDM and fasting plasma
glucose, 2hPG as well as glucose AUC was detected (P <
0.001 for all) which was attenuated after adjustment for
age, BMI, follow-up time, parity, as well as smoking and
physical activity. The association was further attenuated
after adjustment for peripheral insulin sensitivity (Matsuda
ISI) and attenuated or abolished after adjustment for insu-
lin secretion (DI30).
Comparison of the women who proceeded to abnormal
glucose tolerance (AGT, i.e. pre-diabetes or diabetes) afterGDM in the index pregnancy to those who had GDM
but maintained NGT during the follow-up, showed that
the individuals with AGT were significantly older dur-
ing the index pregnancy (P = 0.016) and at the time of
the follow-up study (P < 0.001), but had also a longer
follow-up time (P = 0.008) (Table 4). The women with
AGT at follow-up had higher BMI in the first trimester
of the index pregnancy and also at the follow-up study
visit (P = 0.001 and P < 0.001, respectively). The mean
difference in waist circumference was 7.0 cm between
the progressors and non-progressors (94.0 cm and
87.0 cm, respectively, P < 0.001). Peripheral insulin
sensitivity (Matsuda ISI) was significantly decreased in
patients with AGT (P < 0.001), and insulin secretion
(DI30) was markedly lower in the AGT group as com-
pared to NGT group (P < 0.001).
Figure 1 Glucose tolerance of the control (white columns) and GDM subjects (black columns) evaluated during the follow-up visit
(NGT = normal glucose tolerance, IIFG = isolated increased fasting glucose, IIGT = isolated impaired glucose tolerance, IFG & IGT = combination
of IFG and IGT, type 2 diabetes). The total numbers of study persons in each group are shown in numeric form above each column.
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Our long-term follow-up study shows that pre-diabetes is
very frequent in women with a history of GDM. Gesta-
tional diabetes is strongly associated with both isolated im-
paired fasting glucose, isolated impaired glucose toleranceFigure 2 The cumulative hazard for incident type 2 diabetes (the tim
the controls (broken line) and GDM subjects (black line).and also their combination. Patients with GDM are more
insulin resistant than women who are normoglycemic dur-
ing pregnancy. However, impaired insulin secretion due to
beta cell failure seems to be the key defect leading to the
deterioration of hyperglycemia after a pregnancy affectede point of diagnosis) during the course of the follow-up time in
Table 2 Association between gestational diabetes and the risk of prediabetic stages at the follow-up study
IIFG IIGT IFG + IGT Prediabetes
(N = 267) (N = 26) (N = 40) (N = 333)
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Model 1 3.1 2.4-4.0 <0.001 7.8 2.9-21.6 <0.001 4.7 2.2-10.0 <0.001 4.0 3.1-5.1 <0.001
Model 2 3.2 2.5-4.3 <0.001 7.8 2.8-21.7 <0.001 3.7 1.7-7.9 0.001 3.8 3.0-4.9 <0.001
Model 3 3.0 2.3-4.0 <0.001 7.7 2.7-21.4 <0.001 3.5 1.6-7.6 0.001 3.6 2.8-4.6 <0.001
Model 4 3.1 2.4-4.1 <0.001 7.6 2.7-21.3 <0.001 3.1 1.4-6.9 0.004 3.7 2.8-4.7 <0.001
Cox proportional hazard model comparing the association of GDM with prediabetic stages vs NGT. IIFG, isolated impaired fasting glucose, IIGT, isolated impaired
glucose tolerance, IFG + IGT, combined impaired fasting glucose and impaired glucose tolerance; HR, Hazard ratio: CI, confidence interval. P-values < 0.05 are
indicated in bold font.
Model 1: unadjusted.
Model 2: Adjusted for age, BMI.
Model 3: Adjusted for age, BMI, parity.
Model 4: Adjusted with age, BMI, parity, smoking, physical activity.
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ing the postpartum follow-up period were significant risk
factors for post-partum pre-diabetes or diabetes among
women with a history of GDM, thereby suggesting that
women with GDM could benefit from weight maintenance
or weight loss interventions in the post-partum period.
Pre-diabetes is a preliminary stage of type 2 diabetes,
albeit not all patients with pre-diabetes progress to overt
disease. Approximately one in three of the individuals
with pre-diabetes have been shown to progress to type 2
diabetes in previous studies [11]. Both IFG and IGT
similarly associate with substantially increased risk of de-
veloping diabetes, and the risk is highest in the individ-
uals with combined IFG and IGT. Apart from increased
risk for diabetes, both IFG and IGT have been shown to
associate with increased risk of coronary heart disease in
women [15,16]. In a previous Canadian study of 90 cases
(with either GDM or impaired glucose tolerance during
pregnancy) and 99 normoglycemic controls, GDM status
was significantly associated with IFG at 15-years post-
partum, but not with IGT or pooled pre-diabetes [17].
In our current study of 489 women with GDM and 385
normoglycemic controls, GDM was a significant pre-
dictor of all prediabetic stages separately (IIFG, IIGT,
and IFG&IGT), and in combination at 7.3 years after the
index pregnancy. In our study over 50% of the women
with a history of GDM had developed either pre-
diabetes or diabetes at follow-up (Figure 1), whereas theTable 3 Association between gestational diabetes and plasma
Variable at follow-up study B SE
Fasting plasma glucose (mmol/l) 0.27 0.03
2-hour plasma glucose (mmol/l) 0.54 0.10
Glucose AUC (mmol/l) 83.04 10.84
Linear regression analysis, individuals with diabetes diagnosed between index preg
with GDM. AUC, area under the curve. P-values < 0.05 are indicated in bold font.
P, unadjusted.
P*, adjusted for age, BMI, follow-up time, parity, smoking, physical activity.
P**, adjusted for age, BMI, follow-up time, parity, smoking, physical activity, Matsud
P***, adjusted for age, BMI, follow-up time, parity, smoking, physical activity, Disposcorresponding rate was half of that in the control group.
Our findings are well aligned with previous studies (and
meta-analyses/reviews) estimating the risk of diabetes
following GDM.
Several lifestyle intervention trials have shown a remark-
able reduction of type 2 diabetes risk in individuals with
pre-diabetes. This can be achieved by dietary modifications
and increased physical activity which ameliorate insulin re-
sistance [12,13]. Therefore, diagnosis of pre-diabetes at the
postpartum follow-up after GDM pregnancy serves as a
second alarm and recognizes a subgroup which should
be in a focus of targeted prevention measures for type 2
diabetes.
In our follow-up study waist circumference was greater
in women with a history of GDM when compared to con-
trols, but interestingly so also in the women who proceeded
to prediabetes or diabetes in the subgroup of women pro-
gressed with GDM to abnormal glucose tolerance versus
those with GDM and normal glucose tolerance after preg-
nancy. Waist circumference is closely associated with life-
style, and worryingly, some of the previous studies have
shown that although most women would be aware of the
risk of subsequent risk of diabetes after a GDM pregnancy,
very limited lifestyle changes concerning the eating habits,
weight reduction and/or the level of physical exercise
unfortunately occur [18,19]. Analysis of parous women in
the Diabetes Prevention Program found that women with
GDM had more difficulty complying with the intensiveglucose levels at the follow-up study
P P* P** P***
<0.001 <0.001 <0.001 0.063
<0.001 <0.001 0.011 0.803
<0.001 <0.001 <0.001 0.011
nancy and follow-up study are excluded, N = 385 controls and 474 patients
a ISI.
ition Index.
Table 4 Comparison of women with normal and abnormal glucose tolerance at the follow-up study visit among those
affected by gestational diabetes
NGT (n = 228) AGT (n = 246)
Mean SD Mean SD P
Age at delivery (years) 31.3 5.9 32.6 5.9 0.016
Number of deliveries 1.1 1.4 1.2 1.2 0.550
Age at follow-up study (years) 36.3 7.0 38.6 7.0 <0.001
Follow-up time (years) 5.2 4.0 6.3 4.5 0.008
Waist (cm) 87.0 12.3 94.0 12.6 <0.001
BMI in the first trimester (kg/m2) 25.6 4.6 26.9 4.6 0.001
BMI in the end of pregnancy (kg/m2) 30.1 4.4 31.2 4.5 0.013
Weight increment during pregnancy (kg) 12.3 6.2 12.2 5.9 0.993
BMI at follow-up study (kg/m2) 26.6 4.9 29.5 5.2 <0.001
Change in weight during follow-up time (kg) 1.6 7.3 5.5 8.1 0.002
Change in BMI during follow-up time (kg/m2) 1.1 2.7 2.6 3.0 <0.001
Current smoker (%) 21.8 15.6 0.090
Physical activity (%) 82.7 83.5 0.816
Family history of diabetes 79.9 81.5 0.669
HbA1c [mmol/mol (%)] 35 (5.3) 3 37 (5.5) 4 <0.001
Matsuda ISI (mg/dl, mU/l) 6.8 3.3 4.6 2.8 <0.001
Disposition Index 201.8 61.1 133.0 48.9 <0.001
NGT, normal glucose tolerance; AGT, abnormal glucose tolerance (includes both prediabetes and type 2 diabetes). Subjects diagnosed with type 2 diabetes
between the index pregnancy and the follow-up visit were excluded. P-values < 0.05 are indicated in bold font.
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and therefore women with GDM may require more help
changing their dietary and physical activity behaviors for
the purposes of diabetes prevention [20]. Taking all these
facts into account, systematic follow-up and lifestyle inter-
ventions should be provided to women with a history of
GDM pregnancy, and these should even be intensified if
abnormal glucose tolerance is diagnosed at the follow-up
post-pregnancy. Changing the course of the events before
the development of overt disease helps to reduce the bur-
den of disease associated with micro- and macrovascular
complications, is economically cost-beneficial, and also in-
directly benefits the offspring of GDM patients who are
known to be in increased risk of overweight and metabolic
syndrome [21].
Previous studies have shown that women with a history
of GDM are on average more insulin resistant also in the
non-pregnant state [22]. According to our results, insulin
sensitivity was severely decreased in women with GDM
also after pregnancy. Lifestyle factors including obesity,
especially visceral obesity, and physical inactivity strongly
associate with insulin resistance and type 2 diabetes [23].
During pregnancy, both maternal adiposity and the
insulin-desensitizing effects of placental hormones lead to
progressive insulin resistance which begins near mid-
pregnancy and increases further during the third trimes-
ter. To maintain euglycemia, the pancreas compensates bysecreting increased amounts of insulin. Thus, insulin re-
sistance during pregnancy reveals limitations in insulin se-
cretion and identifies a cohort of relatively young women
with significant a defect in pancreatic beta cell function
[24], and pregnancy has indeed hence been referred to
as the metabolic window into the subsequent metabolic
health in women. On the other hand, increasing insulin
resistance and subsequent insulin hypersecretion eventu-
ally worsen the level of beta cell failure [9]. Our findings
of the insulin secretion defect leading to the failure of
compensatory mechanisms and development of hypergly-
cemia at both fasting and postprandial level are in agree-
ment with this.
The subgroup analysis of the women with a history of
GDM pregnancy showed that those who progressed to
abnormal glucose tolerance (i.e. pre-diabetes or diabetes)
were significantly older and had also a longer follow-up
time (Table 4) which emphasizes the importance of
long-term follow-up. Despite the guidelines of ADA [25]
and the British National Institute for Clinical Excellence
(NICE) [26] which recommend 1–3 yearly follow-up of
glucose homeostasis post-partum, in practice the guide-
lines how to follow these women vary significantly and
the uptake has remained low [27,28]. Diabetes Preven-
tion Programme study in US adults showing that women
with GDM were less able to lose weight and to maintain
exercise after the pregnancy [20]. Our results show that
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the follow-up time were significant risk factors for devel-
oping pre-diabetes or diabetes after GDM pregnancy and
also offer simple means to follow this risk group up by all
healthcare providers. These factors are likely contribute to
their increased risk of developing type 2 diabetes whilst
also highlighting the importance of weight management in
overweight and obese women with a history of GDM. The
number of pregnancies affected by GDM relative to total
number of pregnancies (all vs. only one of the pregnancies
affected by GDM) was not significantly different between
those who remained normoglycemic and those progres-
sing to AGT in the current study (data not shown).
This study is not without limitations. The diagnostic cri-
teria of GDM vary worldwide which makes it difficult to
compare the findings across different populations. Fur-
thermore, our study population was of relatively normal
weight at the index pregnancy, included Caucasian women
only and therefore the results cannot be generalized to
other ethnic groups without caution [29]. The follow-up
times of the study groups differed so that the follow-up
time of controls was significantly longer compared to
women with a GDM history. Thus, the incidence of predi-
abetes and type 2 diabetes is not an overestimate but ra-
ther on the contrary. Taking this into consideration, all
regression analyses were adjusted with the follow-up time.
Conclusions
In conclusion, in the current study we evaluated the long-
term implications of GDM on glucose metabolism in a
large cohort of Finnish women with GDM and healthy
controls. GDM provides an important metabolic window
to the subsequent glucose metabolism in women and of
interest, we observed that pre-diabetic stages were alarm-
ingly prevalent following GDM pregnancy. The timely rec-
ognition of pre-diabetes is of crucial importance for the
prevention of type 2 diabetes before the development of
overt disease. In the current study we observed that women
with GDM history had decreased insulin sensitivity but
hyperglycemia appeared after compensatory insulin secre-
tion mechanism failed. Importantly, a subgroup analysis of
women with GDM history showed that weight and devel-
opment of central obesity were key risk factors of increased
insulin resistance and subsequent progression to prediabe-
tes and type 2 diabetes. This emphasizes the importance of
lifestyle changes after gestational diabetes, especially avoid-
ance of central obesity, which reduce insulin resistance and
thereby stabilize or improve the beta cell defect.
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